Trials / Completed
CompletedNCT00095433
Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
An Extension Study to Evaluate the Safety and Tolerability of Multiple-Dose Intravitreal Injections of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration Who Have Completed the Treatment Phase of a Genentech-Sponsored Phase I or Phase I/II rhuFab V2 Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase III, open-label, multicenter extension study of intravitreally administered ranibizumab in subjects with primary or recurrent subfoveal choroidal neovascularization (CNV) secondary to AMD who have completed the treatment phase of a Genentech sponsored Phase I or Phase I/II ranibizumab protocol (FVF1770g, FVF2128g, or FVF2425g).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhuFab V2 (ranibizumab) |
Timeline
- Start date
- 2002-09-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2004-11-05
- Last updated
- 2014-03-26
Source: ClinicalTrials.gov record NCT00095433. Inclusion in this directory is not an endorsement.